Neobiomics signs agreement with IPS Pharma

Neobiomics announced today an agreement with IPS Pharma, a UK-based services company, to provide UK access of the Proprems®. IPS Pharma has an excellent track record to provide a broad spectrum of specialist dietary foods and dietary supplements.

Under the agreement, IPS Pharma will store, manage and distribute the dietary supplement ProPrems® from its UK based MHRA approved facility.

This collaboration will ensure secure and easy access to ProPrems® in the UK, even in the event of a hard Brexit.

– We are very glad to work with IPS Pharma to help us provide ProPrems® in the UK. Our mission and vision around ProPrems® goes beyond any political turbulence, says Stefan Johansson, founder and CEO of Neobiomics.